跳至主要内容
临床试验/NCT00514111
NCT00514111已完成不适用

Factors Associated to Success of Hepatitis C Therapy

UPECLIN HC FM Botucatu Unesp1 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2007年8月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
100
试验地点
1

研究概览

简要总结

The aim of this study is to evaluate the sustained virologic response (RVS) in HVC patients treated with pegylated-interferon or conventional-interferon and ribavirin, and to investigate the associated factors with RVS, by means of retrospective analysis.

详细描述

Chronic hepatitis C virus(HVC) is a major public-health problem since it presents a long phase of clinical latency which makes its early diagnosis difficult and results in the development of a large number of cases to complications such as cirrhosis, hepatic insufficiency and hepatocarcinoma. In Brazil, it is estimated three million estimated cases to 52 thousand reports. The aim of this study is to evaluate the sustained virologic response (RVS) in HVC patients treated with pegylated-interferon or conventional-interferon and ribavirin, and to investigate the associated factors with RVS, by means of retrospective analysis.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • HVC patients that received specific treatment with pegylated-interferon or conventional-interferon, and ribavirin

排除标准

  • No HVC infection or treatment

研究组 & 干预措施

HVC Patients

HVC patients attended in SAE e HD.

干预措施: pegylated-interferon, conventional-interferon, ribavirin (Drug)

研究者

发起方
UPECLIN HC FM Botucatu Unesp
申办方类型
Other

研究点 (1)

Loading locations...

相似试验